31 reports

Acquisitions, mergers, bankruptcy activities are the key factors to stimulate industry consolidations in China today.

  • Colony Stimulating Factor
  • China
  • Trade
  • Lijun Pharmaceutical Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd

You can easily book an appointment with one online.

  • Colony Stimulating Factor
  • Amgen Inc.
  • Intas Pharmaceuticals Ltd.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Global neutropenia treatment market by G-CSF 2016-2021 ($ millions)
  • G-CSF treatment market

G-CSF treatment market The term ' colony-stimulating factor' comes from the method by which they were isolated.

  • Colony Stimulating Factor
  • World
  • Amgen Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Overview
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Development

GRANULOCYTEMONOCYTE COLONY-STIMULATING FACTOR TRANSGENE EXPRESSION AND CG-## REPLICATION WERE ALSO SUGGESTED.

  • Cancer
  • Colony Stimulating Factor
  • United States
  • World
  • Product Initiative
  • ABSK-021 - DRUG PROFILE
  • SMALL MOLECULES TO INHIBIT CSF-1R FOR ONCOLOGY - DRUG PROFILE

MSB-## acts as colony stimulating factor ## receptor antagonist.

  • Colony Stimulating Factor
  • United States
  • World
  • Company Sales
  • Product Initiative
  • filgrastim
  • Regulatory approval details (US, Europe and Japan)

Endogenous G-CSF is a lineage-specific colony-stimulating factor that is produced by monocytes' fibroblasts, and endothelial cells.

  • Colony Stimulating Factor
  • United States
  • Amgen Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Neupogen group
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Companies Involved in Therapeutics Development

GVAX immunotherapy comprises of two prostate tumor cell lines that have been modified to secrete GM-CSF (granulocytemacrophage colony-stimulating factor) which is an immune stimulatory cytokine and plays a key role in stimulating the body' s immune response.

  • Colony Stimulating Factor
  • Pharmaceutical
  • United States
  • Product Initiative
  • Bolder BioTechnology, Inc.
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Overview
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Product Development Milestones

IT TARGETS GRANULOCYTEMACROPHAGE COLONY STIMULATING FACTOR (GM-CSF).

  • Breast Cancer
  • Colony Stimulating Factor
  • Medical Biotechnology
  • Therapy
  • BriaCell Therapeutics Corp.

(USA) ##.

  • Colony Stimulating Factor
  • Medical Biotechnology
  • Protein Therapy
  • World
  • Market Shares
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Companies Involved in Therapeutics Development

GVAX immunotherapy comprises of two prostate tumor cell lines that have been modified to secrete GM-CSF (granulocytemacrophage colony-stimulating factor) which is an immune stimulatory cytokine and plays a key role in stimulating the body' s immune response.

  • Colony Stimulating Factor
  • Therapy
  • United States
  • Product Initiative
  • Bolder BioTechnology, Inc.

The prominent features of this report are - ##.

  • Chemotherapy
  • Colony Stimulating Factor
  • Therapy
  • World
  • Product Initiative
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Drug Profiles
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Product Development Milestones

ONCOS-##, Targovax' s lead drug candidate, is an engineered oncolytic adenovirus expressing granulocytemacrophage colony stimulating factor (GM-CSF).

  • Colony Stimulating Factor
  • Medical Biotechnology
  • Therapy
  • United States
  • Product Initiative
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Overview
  • PIPELINE BY ADURO BIOTECH INC, H1 2018

It targets granulocytemacrophage colony stimulating factor (GM-CSF).

  • Cancer
  • Colony Stimulating Factor
  • United States
  • World
  • Product Initiative

## ## ## ## ## ## ## China ## ## ## ## ## ## ## ## Russia ## ## ## ## ## ## ## ## Turkey ## ## ## ## ## ## ## ## Mexico ## ## ## ## ## ## ## ## Brazil ## ## ## ## ## ## ## ## Indonesia ## ## ## ## ## ## ## ## CLINICAL TRIALS IN E## COUNT

  • Clinical Trial
  • Colony Stimulating Factor
  • Drug Development
  • World
  • Amgen Inc.

As OPTIMA is an open-label study, depending on enrollment and other factors, interim results from the study may be provided during 2018.

  • Colony Stimulating Factor
  • Pharmaceutical
  • Therapy
  • United States
  • Corporate Finance

Under the agreement, Serendex Pharma has secured access to a unique form of Factor VIIa.

  • Colony Stimulating Factor
  • United States
  • Corporate Finance
  • M&A
  • Mast Therapeutics, Inc.

COLONY-STIMULATING FACTORS UPON BINDING TO SPECIFIC CELL SURFACE RECEPTORS, STIMULATES PROLIFERATION AND DIFFERENTIATION OF HEMATOPOIETIC CELLS.

  • Colony Stimulating Factor
  • Oncology
  • United States
  • World
  • Product Initiative
  • 8.2 COLONY-STIMULATING FACTORS
  • COLONY-STIMULATING FACTORS SEGMENT TO DOMINATE THE U.S. PEGYLATED

FIGURE ## COLONY-STIMULATING FACTORS SEGMENT TO DOMINATE THE U. S.

  • Colony Stimulating Factor
  • Hepatitis
  • North America
  • United States
  • JenKem Technology Co., Ltd
  • PEGFILGRASTIM - DRUG PROFILE

Colony-stimulating factors upon binding to specific cell surface receptors, stimulates proliferation and differentiation of hematopoietic cells.

  • Colony Stimulating Factor
  • Oncology
  • United States
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Blood Disease
  • Clinical Trial
  • Colony Stimulating Factor
  • Drug Development
  • World

The prominent features of this report are - ##.

  • Blood Disease
  • Clinical Trial
  • Colony Stimulating Factor
  • Therapy
  • World
  • GM-CSF: Molgramostim Originator & Biosimilar Products worldwide - 1/2
  • SANOFI

Name ## ## HES-GCSF Granulocyte (Octapharma) Target / Mechanism of Action colony stimulation factor (G-CSF) receptor agonist Class of Compound HESylated rhu protein expressed by a human embryonic kidney (HEK) ##F cell line.

  • Biosimilar
  • Colony Stimulating Factor
  • Medical Biotechnology
  • United States
  • Amgen Inc.

The vaccine candidate stimulates the body immune system to produce antibodies against them.

  • Colony Stimulating Factor
  • Infectious Disease
  • Pharmaceutical
  • Vaccine
  • VBI Vaccines Inc.

The prominent features of this report are - ##.

  • Chemotherapy
  • Clinical Trial
  • Colony Stimulating Factor
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Blood Disease
  • Colony Stimulating Factor
  • Drug Development
  • World
  • Product Initiative

PLINABULIN ACTIVATES GEF-H##, A GUANINE NUCLEOTIDE EXCHANGE FACTOR.

  • Chemotherapy
  • Colony Stimulating Factor
  • Digestive System Disorder
  • Therapy
  • Conatus Pharmaceuticals Inc.

The prominent features of this report are - ##.

  • Blood Disease
  • Colony Stimulating Factor
  • Pharmaceutical
  • World
  • Product Initiative

Its Growth Hormone offers stimulation and production of bone, cartilage and muscle and the body' s primary hormone for stimulating growth during childhood.

  • Chemotherapy
  • Colony Stimulating Factor
  • Neurological Disorder
  • Pharmaceutical
  • Product Initiative
  • Drug Profiles

Pegfilgrastim biosimilar is a longer-lasting version of filgrastim which acts by stimulating colony-stimulating factor (GCSF) receptor.

  • Colony Stimulating Factor
  • Medical Biotechnology
  • Targeted Therapy
  • United States
  • Company Operations

## ## ## Interferon Receptor ## ## ## Kit Ligand (c-Kit Ligand or Steel Factor or Stem Cell Factor or Mast Cell Growth Factor or Familial Progressive Hyperpigmentation ## or EC ##. ##. ##. ##) ## ## ## Target Preclinical Discovery Tota

  • Colony Stimulating Factor
  • European Union
  • Lithuania
  • World
  • Company Operations